tbuckley/cabot-search huggingface dataset:
Underweight Increases the Risk of End-Stage Renal Diseases for Type 2 Diabetes in Korean Population: Data From the National Health Insurance Service Health Checkups 2009–2017
Authors: Yang-Hyun Kim, Jun Goo Kang, Seong Jin Lee, Kyung-do Han, Sung-Hee Ihm, Kyung-Hwan Cho, Yong-Gyu Park
Journal: Diabetes Care (2020)

OBJECTIVE There is a controversy over the association between obesity and end-stage renal disease (ESRD) in people with or without type 2 diabetes; therefore, we examined the effect of BMI on the risk of ESRD according to glycemic status in the Korean population. RESEARCH DESIGN AND METHODS The study monitored 9,969,848 participants who underwent a National Health Insurance Service health checkup in 2009 from baseline to the date of diagnosis of ESRD during a follow-up period of ∼8.2 years. Obesity was categorized by World Health Organization recommendations for Asian populations, and glycemic status was categorized into the following five groups: normal, impaired fasting glucose (IFG), newly diagnosed diabetes, diabetes &amp;lt;5 years, and diabetes ≥5 years. RESULTS Underweight was associated with a higher risk of ESRD in all participants after adjustment for all covariates. In the groups with IFG, newly diagnosed type 2 diabetes, diabetes duration &amp;lt;5 years, and diabetes ≥5 years, the hazard ratio (HR) of the underweight group increased with worsening glycemic status (HR 1.431 for IFG, 2.114 for newly diagnosed diabetes, 4.351 for diabetes &amp;lt;5 years, and 6.397 for diabetes ≥5 years), using normal weight with normal fasting glucose as a reference. The adjusted HRs for ESRD were also the highest in the sustained underweight group regardless of the presence of type 2 diabetes (HR 1.606 for nondiabetes and 2.14 for diabetes). CONCLUSIONS Underweight showed more increased HR of ESRD according to glycemic status and diabetes duration in the Korean population. These associations also persisted in the group with sustained BMI during the study period.
COMPARISON OF SENSITIVITY OF CALCIUM SCORE VERSUS FRAMINGHAM RISK SCORE FOR PREDICTING NEED FOR CORONARY REVASCULARIZATION AS CLINICALLY INDICATED OVER 10-YEAR FOLLOW UP
Authors: Chirag Desai, Phillip Petrasko, Bhavik Patel, Adu Solomon, Patrick Biskupski, Tomasz Stys
Journal: Journal of the American College of Cardiology (2020)
A NOVEL INFLAMMATORY MARKER OF GLYCOSYLATED PROTEINS IS ASSOCIATED WITH CAD AND INCIDENT EVENTS AND DEMONSTRATES AGE EFFECTS IN THE PROMISE TRIAL
Authors: Michel Zeitouni, Stephanie N. Giamberardino, Robert McGarrah, Neha Pagidipati, Geoffrey S. Ginsburg, Udo Hoffmann, Ann Marie Navar, Pamela Douglas, Svati Shah
Journal: Journal of the American College of Cardiology (2020)
GIANT CORONARY ANEURYSM NEEDS MULTIMODALITY IMAGING
Authors: Sarina Sachdev, Landai Nguyen, Hassan Tahir, Muhammad Rafique, Farnoosh Rahimi, Christopher Michael Malozzi, Amod Amritphale, Ghulam Awan, Carl Maltese, Bassam Omar
Journal: Journal of the American College of Cardiology (2020)
DEEP LEARNING FOR AUTOMATIC IDENTIFICATION OF RHEUMATIC HEART DISEASE IN ECHOCARDIOGRAPHIC SCREENING IMAGES: DATA FROM THE ATMOSPHERE-PROVAR STUDY
Authors: Bruno Ramos Nascimento, João Francisco B.S. Martins, Erickson R. Nascimento, Gisele L. Pappa, Craig A. Sable, Andrea Z. Beaton, Paulo R. Gomes, Maria Carmo Nunes, Kaciane K.B. Oliveira, Juliane Franco, Augusto F.C. Pereira, Breno D.F. Rezende, Mariana D.O. Mata, Antonio L. Ribeiro, Wagner Meira
Journal: Journal of the American College of Cardiology (2020)
GPS 5.0: An Update on the Prediction of Kinase-Specific Phosphorylation Sites in Proteins
Authors: Chenwei Wang, Haodong Xu, Shaofeng Lin, Wankun Deng, Jiaqi Zhou, Ying Zhang, Ying Shi, Di Peng, Yu Xue
Journal: Genomics Proteomics & Bioinformatics (2020)

Abstract In eukaryotes, protein phosphorylation is specifically catalyzed by numerous protein kinases (PKs), faithfully orchestrates various biological processes, and reversibly determines cellular dynamics and plasticity. Here we report an updated algorithm of Group-based Prediction System (GPS) 5.0 to improve the performance for predicting kinase-specific phosphorylation sites (p-sites). Two novel methods, position weight determination (PWD) and scoring matrix optimization (SMO), were developed. Compared with other existing tools, GPS 5.0 exhibits a highly competitive accuracy. Besides serine/threonine or tyrosine kinases, GPS 5.0 also supports the prediction of dual-specificity kinase-specific p-sites. In the classical module of GPS 5.0, 617 individual predictors were constructed for predicting p-sites of 479 human PKs. To extend the application of GPS 5.0, a species-specific module was implemented to predict kinase-specific p-sites for 44,795 PKs in 161 eukaryotes. The online service and local packages of GPS 5.0 are freely available for academic research at http://gps.biocuckoo.cn.
Expression of hormone receptors ERα, ERβ and PgR in HER2-positive breast cancers
Authors: M. Litwiniuk, V. Filas, J. Moczko, R. Kaleta, J. Breborowicz
Journal: Journal of Clinical Oncology (2006)

10525 Background: HER-2/neu gene is amplified and overexpressed in 15–20% of invasive breast cancers. HER2-positive breast cancers have a worse prognosis than HER2-negative tumors and distinctive clinical features. They express hormone receptors for estrogen (ERα) and for progesterone (PgR) less frequently than HER2-negative tumors. The identification of the other human estrogen receptor, receptor beta (ERβ), raises a question of ERβ occurrence in HER2-positive breast cancer. Patients and methods: Formalin-fixed, paraffin embedded tissues from 90 patients with invasive HER2-positive breast cancer and from 99 patients with HER2-negative breast cancer were used in this study. The HER2 status was analyzed using HercepTest TM (IHC), and IHC 2+ results were confirmed with FISH test. Immunostaining for ERα, ERβ and PgR was performed using monoclonal antibodies against ERα, PgR (DakoCytomation) and against ERβ (CHEMICON). The EnVision detection system was applied. The data were analyzed using nonparametric Fisher-Freeman-Halton test; the statistical significance was considered when p &lt; 0.5. Results: Only 33% of the HER2-positive breast cancers were ERα-positive compared with 63% in the HER2-negative group (p &lt; 0.001). The expression of ERβ protein was observed in almost equal frequency in both groups (57% of HER2-positive breast cancers and 57.7% of HER2-negative tumors, p = 0.889). The expression of PgR was observed in 30% of HER2-positive breast cancers and in 68.7% of HER2-negative tumors (p &lt; 0.001). Conclusion: The expression of ERβ (unlike that of ERα and PgR) was similar in HER2-positive and in HER2-negative breast cancers. Thus, ERβ may be a potential target in future endocrine therapy for women with HER2-positive breast cancers. No significant financial relationships to disclose.
Pair box (PAX8) protein to predict disease recurrence and its association with outcome in women with endometrial cancer: A retrospective study of 229 patients.
Authors: Damanzoopinder Samrao, Dan Wang, Paulette Mhawech-fauceglia
Journal: Journal of Clinical Oncology (2012)

5091 Background: Pax-8 is a member of the pair-box (PAX) family of transcription factor genes and it has been found to be overexpressed in numerous cancer cell lines including ovarian and endometrial. Possibly, inhibition of Pax8 activity may even have an impact on cancer treatment. However the role of Pax8 in human endometrial cancer has not yet been explored. Thus, the aim of this study is to determine its predictive value in disease outcome of endometrial cancer. Methods: 229 patients with available clinical data and paraffin-embedded tissue were available for review and analysis. The clinical parameters used for modeling were age, histologic subtypes, myometrial depth of invasion, lympho-vascular invasion (LVI), FIGO grade, lymph nodes positive, recurrence, disease status, recurrence time and survival time. To test the association between Pax8 and the clinical parameters, Fisher’s exact test was performed. For survival analysis, Kaplan-Meier method was performed. Results: We found a strong association between PAX8 + and high tumor grade (p=0.002), LVI + (p&lt;0.018), and type II tumor subtype. Patients with tumor expressing Pax8 were more likely to present with shorter OS and DFS p= 0.00096 and p=0.018 respectively. There was an association of PAX8 with OS (p=0.01486) with 5-years OS probability of 80.04% for patients with Pax8- and 55.9% for patients with Pax8+. There was also an association of PAX8 and DFS probability (p=0.02028) with 5-years DFS probability was of 72.12% for patients with Pax8- versus 49.88% for patients with Pax8+ expression. Conclusions: Pax8 is a reliable marker in endometrial cancer and its overexpression can predict poor outcome.
PLASMA AND URINARY C-TYPE NATRIURETIC PEPTIDE AS PROGNOSTIC BIOMARKERS FOR HUMAN ACUTE DECOMPENSATED HEART FAILURE
Authors: Xiao Ma, Yang Chen, Seethalakshmi Iyer, Shawn Reginauld, Christopher Scott, John Burnett, Jeson Sangaralingham
Journal: Journal of the American College of Cardiology (2020)
Abstract 17606: Root Replacement versus More Conservative Management During Type A Acute Aortic Dissection Repair: Insights From the International Registry of Acute Aortic Dissection
Authors: Marco Di Eusanio, M Trimarchi, S Peterson, Myrmel, T Hughes, GC Korach, A Sundt, TM Greason, K Appoo, JJ Milner, R Montgomery, DG Isselbacher, EM Eagle, KA Nienaber, CA Patel, Hj
Journal: Circulation (2013)

Background: How to surgically manage the aortic root in type A acute aortic dissection (TAAAD) is controversial. The aim of this study was to compare short- and mid-term outcomes of root replacemen...
LncSpA: LncRNA Spatial Atlas of Expression across Normal and Cancer Tissues
Authors: Dezhong Lv, Kang Xu, Xiyun Jin, Junyi Li, Yuchen Shi, Mengying Zhang, Xiaoyan Jin, Yongsheng Li, Juan Xu, Xia Li
Journal: Cancer Research (2020)

Abstract Long noncoding RNAs (lncRNA) play important roles in maintaining morphology and function of tissues, and their regulatory effectiveness is closely associated with spatial expression. To provide a comprehensive spatial atlas of expression for lncRNA, we propose LncSpA (http://bio-bigdata.hrbmu.edu.cn/LncSpA) to explore tissue-elevated (TE) lncRNA across human normal and adult and pediatric cancer tissues. In total, 71,131 and 12,007 TE lncRNAs and 634 clinical-related TE lncRNAs were identified across 38 normal and 33 adult cancer tissues. Moreover, 4,688 TE and 413 clinical-related lncRNAs were identified in pediatric cancer. By quick searching or query options, users can obtain eight major types of detailed information for lncRNA via various visualization techniques, including qualitative and quantitative spatial expression in different resources, coexpressed mRNAs, predicted function, known disease association, and the potential to serve as diagnostic or prognostic markers. LncSpA will be a valuable resource to understand lncRNA functions across tissues and cancers, leading to enhanced therapeutic strategies in precision oncology. Significance: LncSpA is a new interactive resource that provides the spatial expression pattern of lncRNA across thousands of normal and cancer samples representing major tissue types.
NATIONWIDE TRENDS OF PREFERRED PACEMAKER IMPLANTATION IN PATIENTS WITH SICK SINUS SYNDROME: A COST-EFFECTIVE ANALYSIS OF SINGLE CHAMBER ATRIAL PACEMAKER VERSUS DUAL CHAMBER PACEMAKER
Authors: Wilbur Freeman, Aiman Miloud Smer, Hussam Abuissa, Amjad Kabach, Alok Saurav
Journal: Journal of the American College of Cardiology (2020)
Abstract 130: Pediatric Cardiac Arrest: Adult Defibrillation Energies are Safe and Effective When Treating a Pediatric Porcine Model
Authors: Laura Davis, Olibhéar McAlister, Ben McCartney, Hannah Torney, Paul Crawford, Rachael Gregson, Rebecca Funston, Adam Harvey, David McEneaney, Eddie Clutton, Jennifer Adgey
Journal: Circulation (2018)

Objective: When attempting defibrillation in an out-of-hospital pediatric patient, the use of a reduced energy is recommended by the resuscitation guidelines due to concerns surrounding potential myocardial damage. This study investigated the effectiveness (first shock success) and safety (myocardial damage) of using adult defibrillation energies in a pediatric model of cardiac arrest. Methods: Twelve piglets (9.5-25.5 kg; typical weight range of 1 to 8 year old children) were anaesthetized and VF was electrically induced. After 15 seconds of untreated VF, defibrillation was delivered using either Protocol A (adult energies; 150J) or Protocol B (pediatric energies; 75J). Following successful defibrillation, a 3 minute rest period was allowed for the heart to recover before VF was again induced. Blood samples were collected and analyzed for cardiac troponin I (cTnI). After 20 shocks were delivered, each animal remained anaesthetized and monitored for 6 hours. Results: A total of 240 shocks were delivered across both protocols with adult and pediatric energies providing comparable first shock success rates of 98.3% (116/118) and 96.6% (112/116). Prior to the induction of VF, Protocols A and B presented with equivalent median (IQR) levels of cardiac damage marker cTnI; 0.04 (0.02, 0.07) ng/ml ( n =6) and 0.05 (0.03, 0.08) ng/ml ( n =6), respectively. Comparable cTnI results were also observed upon completion of the defibrillation phase: Protocol A – 0.23 (0.12, 0.32) ng/ml; Protocol B – 0.20 (0.12, 0.27) ng/ml. There was 100% (12/12) survival after the 6 hour monitoring period with both protocols presenting similar cTnI: Protocol A – 0.32 (0.27, 0.55) ng/ml; Protocol B – 0.28 (0.20, 0.46) ng/ml. There were no clinically significant differences observed between the adult and pediatric defibrillation energy groups. Furthermore, histopathological evaluation revealed no discernible difference in cardiac damage between energy protocols. Conclusion: This study demonstrates that adult defibrillation energies are as effective in terminating VF and do not produce statistically higher levels of cTnI than pediatric defibrillation energies. These results suggest that adult defibrillation energies are appropriate for the treatment of pediatric cardiac arrest.
Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial
Authors: Tiny Jaarsma, Leonie Klompstra, Tuvia Ben Gal, Binyamin Ben Avraham, Josiane Boyne, Maria Bäck, Oronzo Chialà, Kenneth Dickstein, Lorraine Evangelista, Andreas Hagenow, Arno W. Hoes, Eva Hägglund, Massimo F. Piepoli, Ercole Vellone, Nicolaas P.A. Zuithoff, Jan Mårtensson, Anna Strömberg
Journal: European Journal of Heart Failure (2020)

Abstract Aims Exergaming is a new tool to increase physical activity. This study aimed to determine the effects of access to a home‐based exergame (Nintendo Wii) in patients with heart failure (HF) on exercise capacity, self‐reported physical activity and patient‐reported outcome measures. Methods and results We enrolled 605 HF patients in New York Heart Association functional class I–IV, independent of ejection fraction, in an international multicentre randomized controlled trial. Patients were randomized to exergame (intervention) or motivational support (control). The primary endpoint was change in submaximal aerobic exercise capacity as measured by the distance walked in 6 min (6MWT) between baseline and 3 months. Secondary endpoints included long‐term submaximal aerobic exercise capacity, muscle function, self‐reported physical activity, exercise motivation, exercise self‐efficacy at 3, 6 and 12 months. At baseline, patients on average walked 403 ± 142 m on the 6MWT. Patients in the exergame group walked further compared to controls at 3 months (454 ± 123 vs. 420 ± 127 m, P = 0.005), at 6 months (452 ± 123 vs. 426 ± 133 m, P = 0.015) and 12 months (456 ± 122 vs. 420 ± 135 m, P = 0.004). However, correcting for baseline 6MWT values by means of a linear mixed‐effects model revealed no main effect for the intervention on 6MWT. Small significant effects on muscle function were found. Statistically significant treatment effects were found for muscle function but after correction for baseline and confounders, only the treatment effect for the heel‐rise left at 6 months was significant ( P &lt; 0.05). No treatment effect was found for exercise motivation, exercise self‐efficacy, or self‐reported physical activity. Conclusion Exergaming was safe and feasible in patients with HF with different profiles in different health care systems, cultures and climates. However, it was not effective in improving outcomes on submaximal aerobic exercise capacity. Subgroup analysis did not identify specific subgroups benefiting from the intervention. Clinical Trial Registration: ClinicalTrial.gov Identifier: NCT01785121.
ROTATIONAL VERSUS ORBITAL ATHERECTOMY FOR TREATMENT OF DIFFUSE CORONARY IN-STENT RESTENOSIS
Authors: Keisuke Yasumura, Benjamin Benhuri, Yuliya Vengrenyuk, Nitin Barman, Joseph Sweeny, Vishal Kapur, Javed Suleman, Sandeep Mittan, Usman Baber, Roxana Mehran, Gregg Stone, Annapoorna Subhash Kini, Samin K. Sharma
Journal: Journal of the American College of Cardiology (2020)
Homotypic Targeting Delivery of siRNA with Artificial Cancer Cells
Authors: Lingmin Zhang, Sai Deng, Yanfen Zhang, Qingsheng Peng, Huan Li, Ping Wang, Xiaomei Fu, Xueping Lei, Aiping Qin, Xiyong Yu
Journal: Advanced Healthcare Materials (2020)

Abstract The camouflage with cell membrane bestows nanoparticles with cell‐like functions, such as specific recognition, long blood circulation, and immune escaping. For cancer therapy, the nanoparticles camouflaged with cancer cell membrane (CCM) from homologous cells show homotypic targeting delivery of small molecule compounds, photosensitizers, or enzymes to the tumors. However, effective gene therapy encounters difficulties by this approach due to the properties of nucleic acids. Herein, a cancer cell‐like gene delivery system is developed using an excellent polymer poly(β‐amino ester) (PBAE) to condense small interfering RNA (siRNA) (targeting to Plk1 gene) into nanoparticles (PBAE/siPlk1) as the core, which is further camouflaged with CCM. These novel biomimetic nanoparticles CCM/PBAE/siPlk1 (CCMPP) demonstrate highly specific targeting to homotypic cancer cells, effective downregulation of PLK1 level, and inducing apoptosis of cancer cells. Based on the homotypic binding adhesion molecules on the CCM, the cellular internalization and homotypic‐targeting accumulation to the tumors are clearly improved. CCMPP induces highly efficient apoptosis of cancer cells both in vitro and in vivo and results in significant tumor inhibition. The artificial cancer cells with homotypic properties can serve as a biomimetic delivery system for cancer‐targeted gene therapy.
PREDICTORS OF PACEMAKER USE AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Derek Phan, Ming-Sum Lee, Maereg Wassie, Jesse Goitia, Malini Nadadur, Vicken Aharonian, Prakash Mansukhani, Naing Moore, Somjot Brar, Ray Zadegan
Journal: Journal of the American College of Cardiology (2020)
Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis
Authors: Sarah R. Lieber, Benjamin J. Heller, Christopher W. Howard, Robert S. Sandler, Seth Crockett, Alfred Sidney Barritt
Journal: Hepatology (2020)

Background and Aims Anesthesia services for endoscopic procedures have proliferated with the promise of increased comfort and safety. Cirrhosis patients are higher risk for sedation, yet limited data are available describing anesthesia complications in this population. Approach and Results This cross‐sectional study utilized the National Anesthesia Clinical Outcomes Registry, a multicenter quality‐improvement database from 2010 to 2015. Patients with cirrhosis undergoing an endoscopy were identified by International Classification of Diseases, Ninth Revision (ICD‐9)/Current Procedures Terminology (CPT) codes. The outcome of interest was serious anesthesia‐related complication defined as cardiovascular, respiratory, neurological, drug related, patient injury, death, or unexpected admission. A mixed‐effects multivariate logistic regression model determined odds ratios (ORs) between variables and serious complications, adjusting for potential confounders. In total, 9,007 endoscopic procedures were performed among patients with cirrhosis; 92% were esophagogastroduodenoscopies. The majority (81%) were American Society of Anesthesiologists (ASA) class ≥3, and 72% had a history of hepatic encephalopathy, ascites, varices, hepatorenal syndrome, or spontaneous bacterial peritonitis identified by ICD‐9/CPT codes. In total, 87 complications were reported, 33 of which were serious. Frequency of serious complications was 0.4% or 378.6 per 100,000 procedures (95% confidence interval [CI], 260.8, 531.3). The majority of serious complications were cardiovascular (21 of 33), including 15 cardiac arrests. Serious complications were significantly associated with ASA 4 / 5 (OR, 3.84; 95% CI, 1.09, 13.57) and general anesthesia (OR, 4.71; 95% CI, 1.20, 18.50), adjusting for age, sex, ASA class, anesthesia type, inpatient status, portal hypertension history, and variable complication reporting practices. Conclusions Anesthesia complications among endoscopic procedures in cirrhosis are rare overall. Serious complications were predominantly cardiac and associated with sicker patients undergoing general anesthesia. The complexity of end‐stage liver disease may warrant more intensive care during endoscopic procedures, including anesthesia monitoring.
βIII-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer.
Authors: Bertha E. Sanchez, Nilesh Gupta, Meredith Mahan, Evelyn R Barrack, Prem-veer Reddy, Clara Hwang
Journal: Journal of Clinical Oncology (2012)

e15174 Background: Docetaxel is a tubulin-targeting cytotoxic that remains first-line therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) even though half of pts are reported to be non-responders. A predictive marker to identify those who will benefit from docetaxel-therapy will assist clinical decision making. High βIII-tubulin (TUBB3) expression has previously been reported to correlate with lack of response to taxanes in other cancers. We evaluated TUBB3 expression as a predictor of docetaxel-resistance in mCRPC. Methods: mCRPC pts treated with at least 3 cycles of docetaxel between 1990 and 2011 were identified retrospectively. TUBB3 immunostaining was performed on archival formalin-fixed, paraffin-embedded tissue. Stain intensity was scored from 0 to 3; 2 and 3 were interpreted as positive. Rates of PSA response were compared between pts with positive (+) and negative (-) TUBB3 expression. Two definitions of PSA response were evaluated (any PSA decline and at least 50% decline). Overall survival (OS) distribution between TUBB3+ and TUBB3- pts was estimated by the Kaplan-Meier method. Results: Of 73 pts, 26 (35%) expressed TUBB3. At diagnosis, the mean age was 65.7 years and the median Gleason score was 8. At the time of docetaxel therapy, the mean age was 71.2 years, the median PSA level was 70.9 (range, 0.2-5253) and 76% had ECOG performance status ≤1. The median number of docetaxel cycles was 7 (range, 3-18). The total dose of docetaxel was not different between groups (p=0.705). The median OS was 19.2 mo. TUBB3 expression was not correlated with any clinical or pathological characteristic (age, Gleason score, stage, ECOG, PSA, LDH, alkaline phosphatase, hemoglobin, visceral disease or chemotherapy before docetaxel). 65% of TUBB3+ pts had any PSA decline compared to 89% of pts with TUBB3- (p=0.0267). 52% of TUBB3+ pts had a PSA decline of ≥ 50% compared to 70% of TUBB3- pts (p=0.0144). Median OS for TUBB3+ pts was 16.8 mo compared to 20.4 mo in TUBB3- pts (p=0.039). Conclusions: High TUBB3 expression was associated with shorter OS and lower PSA response rates in mCRPC pts treated with docetaxel. These findings need to be validated prospectively.